G1 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

G1 Therapeutics

02/11/2022 13:34

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of 59 cents​​ per share for the quarter ended in September. The
mean expectation of eight analysts for the quarter was for a
loss of 63 cents per share.
    * Revenue rose 385.3% to $23.58 million from a year ago;
analysts
expected $23.28 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 59 cents​.
    * The mean earnings estimate of analysts had risen by
about 7% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * G1 Therapeutics Inc shares had fallen by 12.7% this
quarter and
gained 6.9% so far this year.
    * The company reported a quarterly loss of $25.27 million.
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $32.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
2 at 01:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.63          -0.59          Beat
 Jun. 30 2022      -1.02          -0.92          Beat
 Mar. 31 2022      -0.97          -1.15          Missed
 Dec. 31 2021      -1.03          -0.94          Beat